Adam Berger, MD, FACS

Adam Berger, MD, FACS

Contact Dr. Berger

1100 Walnut Street
MOB, Suite 500
Philadelphia, PA 19107

(215) 955-1622
(215) 923-8222 fax

Most Recent Peer-reviewed Publications

  1. 1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study
  2. Correction to: 1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study
  3. Characterization and Optimal Management of High-risk Pancreatic Anastomoses during Pancreatoduodenectomy
  4. A standardized comparison of peri-operative complications after minimally invasive esophagectomy: Ivor Lewis versus McKeown
  5. Response and resistance to paradox-breaking BRAF inhibitor in melanomas in vivo and Ex vivo
  6. Pancreatogastrostomy Vs. Pancreatojejunostomy: a Risk-Stratified Analysis of 5316 Pancreatoduodenectomies
  7. Surgical approaches to adenocarcinoma of the gastroesophageal junction: the Siewert II conundrum
  8. Monitoring neoadjuvant chemotherapy for breast cancer by using three-dimensional subharmonic aided pressure estimation and imaging with US contrast agents: Preliminary experience
  9. Surgical Apgar score (SAS) predicts perioperative morbidity, mortality, and length of stay in patients undergoing esophagectomy at a high-volume center
  10. Comparative Quantitative Lymph Node Assessment in Localized Esophageal Cancer Patients After R0 Resection With and Without Neoadjuvant Chemoradiation Therapy
  11. VAPC-1 Targeted64Cu-TP3805 kit preparation and its evaluation
  12. Completion dissection or observation for sentinel-node metastasis in melanoma
  13. Pilot study demonstrating metabolic and anti-proliferative effects of in vivo anti-oxidant supplementation with N-Acetylcysteine in Breast Cancer
  14. Incorporation of Procedure-specific Risk into the ACS-NSQIP Surgical Risk Calculator Improves the Prediction of Morbidity and Mortality after Pancreatoduodenectomy
  15. Do intraoperative pyloric interventions predict the need for postoperative endoscopic interventions after minimally invasive esophagectomy?
  16. Patient Symptoms Are the Most Frequent Indicators of Recurrence in Patients with American Joint Committee on Cancer Stage II Melanoma
  17. Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer
  18. 4D subharmonic aided pressure estimation for monitoring neoadjuvant chemotherapy response of breast cancer
  19. Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less
  20. Total minimally invasive esophagectomy for esophageal cancer: approaches and outcomes